BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have been given an average recommendation of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $381.4615.

ONC has been the topic of several research analyst reports. Citizens Jmp boosted their price target on BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Sanford C. Bernstein upgraded BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 target price on the stock in a research report on Monday, January 12th. Royal Bank Of Canada restated an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Citigroup lifted their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, January 21st.

BeOne Medicines Stock Up 2.5%

ONC stock opened at $354.86 on Wednesday. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $330.81 and its 200 day moving average price is $327.88. BeOne Medicines has a 52 week low of $196.45 and a 52 week high of $385.22. The company has a market cap of $38.91 billion, a P/E ratio of 695.80 and a beta of 0.52.

Insider Activity

In related news, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the company’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The SEC filing for this sale provides additional information. Insiders have sold 105,283 shares of company stock worth $32,463,041 over the last ninety days. 6.62% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. EFG International AG purchased a new stake in shares of BeOne Medicines during the fourth quarter worth about $25,000. Anchor Investment Management LLC acquired a new stake in BeOne Medicines during the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $28,000. Leonteq Securities AG purchased a new stake in BeOne Medicines in the 4th quarter worth approximately $35,000. Finally, Daiwa Securities Group Inc. acquired a new position in BeOne Medicines in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.